<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943537</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000664</org_study_id>
    <nct_id>NCT03943537</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders</brief_title>
  <official_title>Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a single center, single dose study of the acute effects of intranasal&#xD;
      insulin on energy metabolism and cognitive function in patients with schizophrenia,&#xD;
      schizoaffective and bipolar disorders, compared and healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychotic disorders are common and severe psychiatric disorders. Despite advances in&#xD;
      understanding the pathophysiology of these disorders, more effective and tolerable treatments&#xD;
      are still needed. Evidence suggests that energy metabolism is altered in psychotic disorders.&#xD;
      The investigators recently developed non-invasive MRI-based techniques to quantify redox&#xD;
      balance and ATP generation in the brain. Targeting insulin pathways in the brain may allow&#xD;
      for modulating abnormalities in energy metabolism. The investigators seek to examine whether&#xD;
      intranasal insulin can modulate energy metabolism and improve cognition in patients with&#xD;
      psychotic disorders. The study will use magnetic resonance spectroscopy (MRS) technology to&#xD;
      measure in vivo energy metabolism processes in the brain, before and after the administration&#xD;
      of intranasal insulin. Investigators will also measure changes in cognition with the&#xD;
      administration of intranasal insulin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in brain redox state</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in brain NAD+/NADH ratio as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brain ATP</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in ATP concentration as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brain PCr</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in Phosphocreatine (PCr) concentration as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brain CK</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in creatine kinase (CK) enzyme rate as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in cognitive function</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in STROOP assessment color-word condition interference score. This score is calculated as follows, with C being the number of items answered correctly in the color condition, W being the number answered correctly in the word condition, and CW being the number of items answered correctly in the color-word condition: CW - (C x W)/(C+W). Higher scores indicate better cognitive function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in domain-specific cognitive function.</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in BACS domain subscale scores (domain, range): working memory, 0-36; attention, 0-110; and verbal fluency, number of words generated over 60-sec trials. Higher scores indicate better cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in brain pH.</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in pH as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain inorganic phosphate concentration.</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in inorganic phosphate (Pi) concentration as measured by in vivo 31P magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose levels.</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Safety outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in brain Gln, Glu and GSH</measure>
    <time_frame>6 hours, pre- and post- 40 IU intranasal insulin</time_frame>
    <description>Changes in glutamine (Gln), glutamate (Glu), and glutathione (GSH) concentration as measured by in vivo proton magnetic resonance spectroscopy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psychosis</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizo Affective Disorder</condition>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin (40 IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Insulin</intervention_name>
    <description>40 units Novolin R administered intranasally using ViaNase device.</description>
    <arm_group_label>Intranasal Insulin (40 IU)</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses of&#xD;
             schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features OR&#xD;
&#xD;
          -  Healthy Controls (no history of DSM psychiatric diagnoses, nor history of the same in&#xD;
             first-degree relatives)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric hospitalization within the last 4 weeks&#xD;
&#xD;
          -  Unstable/active disease or potential contraindications, such as liver disease, kidney&#xD;
             disease, uncontrolled hypertension, significant or unstable medical illness&#xD;
&#xD;
          -  Currently prescribed: antidiabetic agents, including oral antidiabetic medications and&#xD;
             insulin, intranasal medication, steroids, weight loss agents, protease inhibitors, or&#xD;
             NRTI's.&#xD;
&#xD;
          -  Pregnant or breast-feeding, not using an effective form of contraception for at least&#xD;
             3 months, and/or not abstinent for 1 month prior to enrollment&#xD;
&#xD;
          -  History of significant head injury&#xD;
&#xD;
          -  Contraindication to MRI scans (claustrophobia, cardiac pacemakers, metal clips and&#xD;
             stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc.,&#xD;
             brain stimulator devices, implanted drug pumps, ear implants, eye implants or known&#xD;
             metal fragments in eyes, exposure to shrapnel or metal filings, other metallic&#xD;
             surgical hardware in vital areas, certain tattoos with metallic ink, certain&#xD;
             transdermal patches, metal-containing IUDs).&#xD;
&#xD;
          -  Medical conditions preventing blood draws&#xD;
&#xD;
          -  History of electroconvulsive therapy (ECT) within the last 6 months&#xD;
&#xD;
          -  BMI &gt; 35 or body weight &gt; 350 lbs&#xD;
&#xD;
          -  DSM diagnosis of substance use disorder in the past 6 months&#xD;
&#xD;
          -  For Healthy Controls:&#xD;
&#xD;
          -  Taking medication other than birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret Gardner</last_name>
    <phone>617-855-2489</phone>
    <email>mgardner@mclean.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dost Ongur</last_name>
    <phone>617-855-3922</phone>
    <email>DONGUR@PARTNERS.ORG</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Virginie-Anne Chouinard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dost Ongur, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Dost Ongur</investigator_full_name>
    <investigator_title>Director, Schizophrenia and Bipolar Disorder Research Program</investigator_title>
  </responsible_party>
  <keyword>Psychosis</keyword>
  <keyword>Insulin</keyword>
  <keyword>Brain Metabolism</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

